DelveInsight’s “Arthralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Arthralgia, historical and forecasted epidemiology as well as the Arthralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Arthralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Arthralgia Market Forecast
Some of the key facts of the Arthralgia Market Report:
-
The Arthralgia market size is estimated to grow with a significant CAGR during the study period (2019-2032)
-
Arthralgia affected women more than it did men, according to DelveInsight's data. For example, in Japan in 2021, there were about 34,000 cases of Arthralgia in males and about 39,000 in females.
-
Key Arthralgia Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others
-
Key Arthralgia Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab and others
-
The Arthralgia epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases
-
The Arthralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Arthralgia pipeline products will significantly revolutionize the Arthralgia market dynamics.
Arthralgia Overview
Arthralgia is a medical term used to describe pain or discomfort in one or more joints. Joints are the connections between bones, and arthralgia can affect various parts of the body, such as the knees, elbows, wrists, or shoulders. The pain associated with arthralgia can be caused by inflammation, injury, infection, or other underlying conditions affecting the joints.
Get a Free sample for the Arthralgia Market Report:
https://www.delveinsight.com/report-store/arthralgia-market
Arthralgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Arthralgia Epidemiology Segmentation:
The Arthralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Arthralgia
-
Prevalent Cases of Arthralgia by severity
-
Gender-specific Prevalence of Arthralgia
-
Diagnosed Cases of Episodic and Chronic Arthralgia
Download the report to understand which factors are driving Arthralgia epidemiology trends @ Arthralgia Epidemiology Forecast
Arthralgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Arthralgia market or expected to get launched during the study period. The analysis covers Arthralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Arthralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Arthralgia Therapies and Key Companies
-
ILUMYA: Sun Pharma
-
Deucravacitinib: Bristol-Myers Squibb
-
Bimekizumab: UCB Biopharma
-
Izokibep: Affibody AB
-
SUNPG18_07: Sun Pharmaceutical Industries Limited
-
VTX958: Ventyx Biosciences, Inc
-
ATI-450: Aclaris Therapeutics, Inc.
-
Risankizumab: AbbVie
-
Upadacitinib: AbbVie
-
AIN457: Novartis
-
Ustekinumab: Janssen Research & Development, LLC
-
Sonelokimab: MoonLake Immunotherapeutics AG
Discover more about therapies set to grab major Arthralgia market share @ Arthralgia Treatment Market
Arthralgia Market Strengths
-
Increased prevalence, growth in awareness, and lifestyle changes have necessitated changes in the diagnosis and treatment of PsA in the recent decade
-
Various screening tools, including self-administered questionnaires, have been developed to help dermatologists, rheumatologist, and general physicians to identify patients who might suffer from PsA
Arthralgia Market Unmet Needs
-
Lack of biomarkers
-
Challenges in current treatment options
-
Challenges in current guidelines
-
Poor disease understanding
-
Challenges in managing comorbidities
Scope of the Arthralgia Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Arthralgia Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others
-
Key Arthralgia Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others
-
Arthralgia Therapeutic Assessment: Arthralgia current marketed and Arthralgia emerging therapies
-
Arthralgia Market Dynamics: Arthralgia market drivers and Arthralgia market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Arthralgia Unmet Needs, KOL’s views, Analyst’s views, Arthralgia Market Access and Reimbursement
To know more about Arthralgia companies working in the treatment market, visit @ Arthralgia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Arthralgia Market Report Introduction
2. Executive Summary for Arthralgia
3. SWOT analysis of Arthralgia
4. Arthralgia Patient Share (%) Overview at a Glance
5. Arthralgia Market Overview at a Glance
6. Arthralgia Disease Background and Overview
7. Arthralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Arthralgia
9. Arthralgia Current Treatment and Medical Practices
10. Arthralgia Unmet Needs
11. Arthralgia Emerging Therapies
12. Arthralgia Market Outlook
13. Country-Wise Arthralgia Market Analysis (2019–2032)
14. Arthralgia Market Access and Reimbursement of Therapies
15. Arthralgia Market Drivers
16. Arthralgia Market Barriers
17. Arthralgia Appendix
18. Arthralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
